-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Conmed, Lowers Price Target to $68

Benzinga·07/31/2025 13:55:51
Listen to the news
Piper Sandler analyst Matt O'Brien maintains Conmed (NYSE:CNMD) with a Overweight and lowers the price target from $80 to $68.